Oramed Pharmaceuticals (NASDAQ:ORMP) Upgraded by StockNews.com to Hold Rating

Oramed Pharmaceuticals (NASDAQ:ORMP) was upgraded by stock analysts at StockNews.com from a “sell” rating to a “hold” rating in a research report issued on Monday.

Oramed Pharmaceuticals Trading Down 1.3 %

Shares of NASDAQ:ORMP traded down $0.03 on Monday, hitting $2.36. 176,406 shares of the company were exchanged, compared to its average volume of 108,429. The firm has a market capitalization of $95.14 million, a P/E ratio of 21.45 and a beta of 1.67. Oramed Pharmaceuticals has a 1-year low of $2.00 and a 1-year high of $3.67. The stock’s 50 day moving average price is $2.38 and its 200 day moving average price is $2.41.

Institutional Trading of Oramed Pharmaceuticals

Large investors have recently added to or reduced their stakes in the company. Murchinson Ltd. lifted its holdings in shares of Oramed Pharmaceuticals by 0.5% during the third quarter. Murchinson Ltd. now owns 1,708,879 shares of the biotechnology company’s stock worth $4,170,000 after purchasing an additional 8,889 shares during the period. XTX Topco Ltd raised its position in Oramed Pharmaceuticals by 59.7% during the 3rd quarter. XTX Topco Ltd now owns 24,716 shares of the biotechnology company’s stock worth $60,000 after buying an additional 9,242 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in Oramed Pharmaceuticals by 52.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 31,470 shares of the biotechnology company’s stock valued at $81,000 after acquiring an additional 10,774 shares during the period. Renaissance Technologies LLC boosted its holdings in shares of Oramed Pharmaceuticals by 89.0% in the 2nd quarter. Renaissance Technologies LLC now owns 230,800 shares of the biotechnology company’s stock valued at $593,000 after acquiring an additional 108,700 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of Oramed Pharmaceuticals in the third quarter worth $272,000. Hedge funds and other institutional investors own 12.73% of the company’s stock.

Oramed Pharmaceuticals Company Profile

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.